Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
PLoS One. 2012;7(11):e48775. doi: 10.1371/journal.pone.0048775. Epub 2012 Nov 7.
Disseminated Candida albicans infection results in high morbidity and mortality despite treatment with existing antifungal drugs. Recent studies suggest that modulating the host immune response can improve survival, but specific host targets for accomplishing this goal remain to be identified. The extracellular matrix protein thrombospondin-1 is released at sites of tissue injury and modulates several immune functions, but its role in C. albicans pathogenesis has not been investigated. Here, we show that mice lacking thrombospondin-1 have an advantage in surviving disseminated candidiasis and more efficiently clear the initial colonization from kidneys despite exhibiting fewer infiltrating leukocytes. By examining local and systemic cytokine responses to C. albicans and other standard inflammatory stimuli, we identify a crucial function of phagocytes in this enhanced resistance. Subcutaneous air pouch and systemic candidiasis models demonstrated that endogenous thrombospondin-1 enhances the early innate immune response against C. albicans and promotes activation of inflammatory macrophages (inducible nitric oxide synthase⁺, IL-6(high), TNF-α(high), IL-10(low)), release of the chemokines MIP-2, JE, MIP-1α, and RANTES, and CXCR2-driven polymorphonuclear leukocytes recruitment. However, thrombospondin-1 inhibited the phagocytic capacity of inflammatory leukocytes in vivo and in vitro, resulting in increased fungal burden in the kidney and increased mortality in wild type mice. Thus, thrombospondin-1 enhances the pathogenesis of disseminated candidiasis by creating an imbalance in the host immune response that ultimately leads to reduced phagocytic function, impaired fungal clearance, and increased mortality. Conversely, inhibitors of thrombospondin-1 may be useful drugs to improve patient recovery from disseminated candidiasis.
播散性白念珠菌感染尽管采用现有抗真菌药物治疗,但仍导致高发病率和死亡率。最近的研究表明,调节宿主免疫反应可以提高存活率,但实现这一目标的特定宿主靶标仍有待确定。细胞外基质蛋白血小板反应蛋白-1在组织损伤部位释放,并调节几种免疫功能,但它在白念珠菌发病机制中的作用尚未被研究。在这里,我们表明缺乏血小板反应蛋白-1的小鼠在播散性念珠菌病中具有生存优势,并且尽管肾脏中的初始定植清除效率较低,但更有效地清除肾脏中的初始定植。通过检查对白念珠菌和其他标准炎症刺激物的局部和全身细胞因子反应,我们确定了吞噬细胞在这种增强的抵抗力中的关键作用。皮下气囊和全身念珠菌病模型表明,内源性血小板反应蛋白-1增强了对白念珠菌的早期固有免疫反应,并促进了炎症性巨噬细胞(诱导型一氧化氮合酶+,IL-6(高),TNF-α(高),IL-10(低))的激活,趋化因子 MIP-2、JE、MIP-1α 和 RANTES 的释放以及 CXCR2 驱动的多形核白细胞募集。然而,血小板反应蛋白-1在体内和体外抑制了炎症性白细胞的吞噬能力,导致肾脏中的真菌负担增加,野生型小鼠的死亡率增加。因此,血小板反应蛋白-1通过在宿主免疫反应中造成不平衡,从而导致吞噬功能降低、真菌清除能力受损和死亡率增加,从而增强播散性念珠菌病的发病机制。相反,血小板反应蛋白-1抑制剂可能是改善播散性念珠菌病患者恢复的有用药物。